Linzagolix choline

Since being founded in 2012, ObsEva had racked up losses of $482.7 million. With its money and options dwindling, ObsEva has finally decided to wind down operations and lay off all its employees. The writing has been on the wall for the Swiss biotech since July 2022, when the company’s Nasdaq stock nosedived in the wake of the FDA’s claim that ObsEva’s highly touted uterine fibroid candidate linzagolix wasn’t fit for an on-time approval. In response, the company announced a 70% reduction in workforce two months later, with the remaining staff focused on preterm labor treatment ebopiprant and oral oxytocin receptor agonist nolasiban. By November 2022, the company had sold off ebopiprant to Xoma in an attempt to resuscitate its share price. When that failed, the company let go of its Boston-based executives—including CEO Brian O’Callaghan—and consolidated its remaining operations in Switzerland in February 2023. The company’s narrower focus became nolasiban, which it was investigating as a way to improve in vitro fertilization success rates. The company delisted from the Nasdaq the following month but has now informed the SIX Swiss Exchange's listing authority that it is “likely not going to be able to satisfy the requirements for maintaining its listing on SIX.” The Geneva-based company has secured a four-month moratorium from being chased by creditors for its debts until the end of May while it winds downs operations. Current CEO Fabien de Ladonchamps informed investors last month that ObsEva was “currently engaged in advanced negotiations for a transaction pertaining to nolasiban.” “While we are pursuing our efforts to monetize nolasiban, our compound designed to increase live birth rate for women undergoing IVF, ObsEva's cash position remains low, which compromises our ability to keep operating the company with existing workforce and to have financial statements prepared,” de Ladonchamps said in this morning's release. While de Ladonchamps' employment will be terminated along with all of his colleagues', ObsEva said he will “remain in function during the notice period for the duration of the moratorium process and beyond, as needed.” At its last earnings report back in the summer, ObsEva revealed that the $3.3 million it had available in cash and equivalents was likely to run out by the end of last year. Since being founded in 2012, the biotech had racked up losses of $482.7 million and “expects to continue to generate operating losses for the foreseeable future,” it said at the time.

DUBLIN, Aug. 4, 2023 /PRNewswire/ -- The "Women's Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Hormonal Infertility, Endometriosis & Uterine Fibroids, Contraceptives), By Age, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering. The global women's health market is projected to reach USD 63.02 billion by 2030, with a compound annual growth rate (CAGR) of 5.4% from 2023 to 2030. Market Dynamics Market Drivers: Rising incidence of target diseases such as endometriosis and uterine fibroids. Factors like child or early marriages leading to a need for women's health products and services. Increasing initiatives by governments and various organizations to promote women's health and family planning. Growing adoption of publicly funded family planning services. Market Restraints: Patent expiry of major drugs leading to increased competition from generic drugs. Lawsuits related to women's health products, leading to regulatory challenges. Adverse effects associated with the use of contraceptive drugs and devices, impacting consumer confidence. The introduction of innovative products and a robust pipeline of women's health products are key drivers of market growth. For example, the FDA approved Myfembree, developed by Pfizer Inc. and Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. Support from organizations like the Bill & Melinda Gates Foundation for family planning initiatives is expected to fuel market growth. Endometriosis is also a significant concern, affecting around 190 million reproductive-age girls and women globally. However, the COVID-19 pandemic negatively impacted the market, with measures like social distancing and lockdowns affecting treatment facilities and gynecological clinics. In low- and middle-income countries, the usage of contraceptives declined due to pandemic-related disruptions. Strategic initiatives by key players, such as collaborations and partnerships, are anticipated to drive market growth. However, competition from generic drugs and pricing pressure after patent expiration may hinder growth. North America currently dominates the global market due to favorable reimbursement policies, key market players' presence, supportive government regulations, and high contraceptive usage among women. The Asia Pacific region is expected to grow at the fastest CAGR, driven by increased government spending on women's health. Women's Health Market Report Highlights Contraceptives segment holds the highest market share due to increased family planning awareness and technological advancements. Endometriosis segment is expected to witness significant growth with the launch of products like Relugoliz and the impending launch of Linzagolix. The 50 years and above age segment is projected to register the fastest growth rate as life expectancy increases, leading to a larger menopausal population. Globally, women aged between 45 and 55 years typically experience menopause, with the average age of onset at 51.5 years according to the International Menopause Society. Key Topics Covered Chapter 1 Methodology and Scope Chapter 2 Executive Summary Chapter 3 Women's Health Market Variables, Trends & Scope 3.1 Women's Health Market Lineage Outlook 3.2 Penetration & Growth Prospect Mapping 3.3 Regulatory and Reimbursement Framework 3.4 Market Dynamics 3.5 Women's Health Market Analysis Tools 3.6 Major Deals and Strategic Alliances 3.7 Women's Health Market Analysis Tools 3.8 Market size estimates for key products (global level estimates and forecasts) Chapter 4 Application Business Analysis 4.1 Women's Health Market: Application Movement Analysis 4.2 Postmenopausal Osteoporosis 4.3 Hormonal Infertility 4.4 Endometriosis and Uterine Fibroids 4.5 Contraceptives 4.6 Menopause 4.7 Polycystic Ovary Syndrome (PCOS) Chapter 5 Age Segment Analysis 5.1 Women's Health Market: Application Movement Analysis 5.2 50 years and above 5.3 Others Chapter 6 Regional Business Analysis 6.1 Women's Health Market: Regional Outlook 6.2 North America 6.3 Europe 6.4 Asia Pacific 6.5 Latin America 6.6 Middle East and Africa Chapter 7 Competitive Landscape 7.1 Company Categorization 7.2 Strategy Mapping 7.3 Key Company Market Share Analysis, 2022 7.4 Company Profiles AbbVie, Inc. Bayer AG Merck & Co. Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Agile Therapeutics Amgen, Inc. Apothecus Pharmaceutical Corp. Blairex Laboratories, Inc.) Ferring B.V. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets